Edgewise Therapeutics

About:

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Website: https://www.edgewisetx.com

Top Investors: Wellington Management, Deerfield, RA Capital Management, OrbiMed, Cormorant Asset Management

Description:

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

Total Funding Amount:

$539M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Boulder, Colorado, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)edgewisetx.com

Founders:

Alan Russell, Badreddin Edris, Peter Thompson

Number of Employees:

51-100

Last Funding Date:

2024-01-19

IPO Status:

Public

© 2025 bioDAO.ai